New Data Updates - Our P1NP/CTX Ratio Framework

Key takeaways: P1NP/CTX ratio framework for bone health

• Osteoporosis is framed as generally preventable and sometimes reversible when you use the right information and execute consistently.
• The video emphasizes using bone turnover markers (blood tests) to get faster feedback than imaging:
  • DEXA changes can take 1–2 years
  • Remodeling imaging may take ~6–24 months
  • Bone turnover markers can indicate whether interventions are working sooner.

Bone turnover markers explained (and why they matter)

• P1NP (P1 and P): produced by osteoblasts → reflects bone building
• CTX: released by osteoclasts → reflects bone breakdown

Instead of using either test alone, the video argues you should assess both sides of bone metabolism.

Core strategy: use the ratio P1NP/CTX (not either test in isolation)

The evidence-based ratio method discussed:

• Compute: (P1NP) / (CTX adjusted for units)
• Unit-adjustment approach (as described):
  • CTX is measured in different units than P1NP
  • Convert CTX into compatible units by shifting the decimal based on the unit scale so the result falls within the target interpretive range.

Interpretation rule of thumb:

• Ratio typically falls between 50 and 300
• Higher trends toward bone building
• Lower trends toward bone breakdown

Thresholds / “zones” to assess fracture risk (from discussed studies)

Based on the 2017 observational study (Fischer et al., 2017) and a 2018 follow-up refinement discussed:

• Under 100: red zone / highest fracture risk
• 100–130: yellow zone (“unknown/likely at risk”); risk increases vs higher ratios
• 130–150: neutral/stable zone
  • Fracture risk plateaus—not meaningfully better than >150, per the speaker’s interpretation
• Over 150: protective / “anabolic” zone
• Over 200: really good / highly protective

Practical self-care / action steps implied by the framework

• Use bone turnover markers for quicker feedback than waiting for DEXA/other imaging.
• If your ratio is low:
  • Treat it as a signal that your current lifestyle/supplement plan may need adjustment to improve bone turnover toward building.
• If you’re in the gray zone (100–150):
  • The video’s main reassurance is that not hitting 150+ immediately may not automatically mean you’re failing—fracture risk may already be neutral around ~130–150.
• Measurement consistency matters, especially for CTX:
  • CTX has diurnal variation
  • Best practice described:
    • Morning, fasted labs
    • Same conditions each time
    • Control factors like:
      • hormone timing/cycling
      • premenstrual cycle timing (if applicable)
      • sleep/work schedule consistency

How treatment or drugs can affect interpretation

If someone is on anti-resorptive or bone-metabolism drugs, results can look “skewed”:

• Bisphosphonates:
  • May produce very low turnover
  • The speaker says the ratio can still be useful for monitoring once
• Prolia (denosumab):
  • Described as pushing toward a catabolic phase / suppressing markers differently
  • Speaker preference noted: bisphosphonate favored “under the right circumstances”

Monitoring frequency guidance from the video:

• If on a stable dose, measure once to understand response
• No need to keep re-measuring repeatedly while the dose remains unchanged

Limitations acknowledged by the speaker

• The highlighted evidence is largely from observational data, not randomized fracture-tracking trials.
• The main study population described is older (mean age ~78), hospitalized, so results may not perfectly extrapolate to younger postmenopausal individuals.
• Drug use and CTX timing/variance can limit comparability if labs aren’t standardized.

Presenters / sources

• Presenter: Dr. Doug (Dr. Doug show)
• Study/source names mentioned:
  • Fischer — 2017 study in Clinical Interventions in Aging
  • A follow-up / 2018 study (referenced by the speaker, but full citation details not provided)